about
Binding of ADAMTS13 to von Willebrand factorADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factorShiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function.Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpuraThrombotic microangiopathy with targeted cancer agentsMembrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndromePathogenesis of thrombotic microangiopathiesHemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimersCancer-associated thrombotic microangiopathyHeparin-induced thrombocytopenia in solid organ transplant recipients: The current scientific knowledgeEndothelial cell control of thrombosisProteolytic processing of von Willebrand factor by adamts13 and leukocyte proteasesAtypical hemolytic-uremic syndrome: a case report and literature reviewCatastrophic antiphospholipid syndrome: a clinical reviewRelevance of ADAMTS13 to liver transplantation and surgeryCoagulation abnormalities in critically ill patientsCleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditionsThe von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura (TTP)The CXCR1/2 ligand NAP-2 promotes directed intravascular leukocyte migration through platelet thrombiIncreased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivoShigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice.A rare presentation of micro-angiopathic haemolytic anaemia in a critically ill patient: a case reportAntineoplastic agents and thrombotic microangiopathy.Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing bloodThe interaction between factor H and Von Willebrand factor.Automated measurement of schistocytes after bone marrow transplantation.Attack of the acronyms: TTP, VWF, ADAMTS-13 and SELDI-TOF-MS.A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry.Hemolytic uremic syndrome following the infusion of oxaliplatin: case report.Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse.Comparison of Shiga toxin production by hemolytic-uremic syndrome-associated and bovine-associated Shiga toxin-producing Escherichia coli isolates.A perspective on the measurement of ADAMTS13 in thrombotic thrombocytopaenic purpura.Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods.Deficiency of ADAMTS-13 in thrombotic and thrombocytopenic purpura.Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countriesMutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.Excellent response of refractory life-threatening thrombotic thrombocytopenic purpura to cyclosporine treatment.Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura.Acute thrombotic thrombocytopenic purpura following doxycycline treatment of Chlamydia pneumoniae infection in a patient with dermatomyositis.
P2860
Q24299876-B4EBB0D6-AB98-452A-8DD0-6C3EB2DD0A6AQ24303587-F01E7AC1-7F90-4207-8705-A3F0E6D4812EQ24538771-667903E9-C028-460A-AA0B-655ADEFC4280Q24620546-844DA3CC-5DC6-4E7C-9FD3-8404C4177082Q24635904-B9E76972-E3A5-45AC-AE51-E050DB8318B9Q24650823-7BDE0658-308E-440F-A62E-52CA61DB20AAQ24658043-A0E69A8E-85E7-4ED0-A95E-6E1D96ED86ACQ24669689-16F10395-5EF7-4461-AE64-5F7DC7670CCBQ26738984-6D987142-C139-4806-80B5-5EC590EFAC35Q26751442-F0386127-127A-439B-895F-2B4687E1271EQ26781779-B71C1C6F-D63C-416C-8D35-28BFFD8391DEQ26827966-AB625C9A-B883-40B1-9F15-37359C4B128DQ27003863-378C29E8-5052-4EFD-8D1A-E392456726ECQ27009935-9E524901-28E0-42E6-9FE0-038F8D2DAE80Q28085109-0CE12986-6D22-40B4-8315-B3D636A7EBBEQ28199912-A69965F0-AA63-4FBA-B9A3-58C081496821Q28267403-82246CE8-D776-41B8-BF7C-F5B7D7AB30C0Q28305837-62C126C3-E5F3-4E9F-A0C8-FC209017C361Q28513807-2F1B0520-EB3C-4B19-B696-2781E530393AQ28584350-A80FBC98-4CC0-437A-B2CC-6222C7A9C1F7Q28594414-83A2CE11-DE8E-48CA-89D9-73009ED4FAA6Q28751694-F5998C30-6C3D-4E53-9DAA-0676181F623BQ30251919-FB1C6FA5-5FB2-4D10-9215-2BACB7A1BBD2Q30479643-6C05A426-483A-4FBC-B44F-1667C9E4250DQ31133820-C52E29DE-3598-4A25-80F8-45C263723877Q33204276-759D7107-A6D6-4C1E-BCDE-9356FC188736Q33231921-D9B709B3-7D47-460D-8CBD-2A5670A7A3E3Q33231922-360CDE4B-0669-4D04-9AA4-8A06887E8576Q33257302-2A51A425-16F7-4E5E-AF93-7EF1B9D5B5FCQ33327295-486DB364-19CF-4354-82B7-BC65E204A1A3Q33346383-3755B5D8-3D3B-403A-AD0A-8665F1B14AABQ33347147-E15DC6FA-102E-4131-B8B5-DBA69475BC09Q33349688-0733946E-C385-4915-A493-C5F547A76380Q33349696-F0D75E94-D2A7-47D0-A636-13F77C5D961BQ33349831-97769880-2DF4-48A4-BBC0-E6AC2DF3A71CQ33357218-E3E3831E-3F9C-4AA2-9737-2EFB1C2A50C8Q33358683-5CAE67EB-CF09-4377-9700-F2F751772042Q33359905-4180EE93-0CDA-4462-BB25-C5FEF9E11943Q33360049-47D797CE-02C9-4096-A62D-7E8AD6E6B61CQ33360207-A47BBEBF-B9AB-4B1A-BBB1-7C1BFD2F0AA1
P2860
description
im August 2002 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2002
@uk
name
Thrombotic Microangiopathies
@en
Thrombotic Microangiopathies
@nl
type
label
Thrombotic Microangiopathies
@en
Thrombotic Microangiopathies
@nl
prefLabel
Thrombotic Microangiopathies
@en
Thrombotic Microangiopathies
@nl
P356
P1476
Thrombotic Microangiopathies
@en
P2093
Joel L. Moake
P304
P356
10.1056/NEJMRA020528
P407
P577
2002-08-22T00:00:00Z